BMO reiterates Eli Lilly stock with $900 target on SiteOne deal

BMO Capital reiterated its Outperform rating on Eli Lilly (LLY) with a $900 price target, as the company announced its acquisition of SiteOne Therapeutics for up to $1 billion to expand its pain management portfolio and compete with Vertex. The acquisition follows positive analyst sentiment, with InvestingPro data showing upward earnings revisions and analysts noting the strategic benefit of the deal given SiteOne's Phase 2 ready Nav 1.8 inhibitor, STC-004. Recent developments also include Australian approval of Kisunla for early Alzheimer's and maintained Overweight/Outperform ratings from Morgan Stanley and Bernstein, respectively, reflecting confidence in Lilly's GLP-1 market leadership and growth prospects.

Analysis

Eli Lilly (LLY) is strategically expanding its therapeutic portfolio through the acquisition of SiteOne Therapeutics for up to $1 billion, a move designed to bolster its presence in the pain management sector and establish competition with entities such as Vertex. This acquisition, viewed as a strategic positive by BMO Capital which maintained its Outperform rating and $900 price target, grants Eli Lilly access to STC-004, a Phase 2 ready Nav 1.8 inhibitor, utilizing a validated mechanism in pain treatment at what is considered an attractive price. Eli Lilly's financial strength is underscored by its $650 billion market capitalization, impressive 36% revenue growth over the last twelve months, and a robust 82% gross profit margin, facilitating such strategic growth initiatives. Analyst sentiment is notably positive, with InvestingPro data indicating seven recent upward earnings revisions, and strong endorsements from Morgan Stanley (Overweight, $1,133 target) and Bernstein (Outperform, $1,100 target), reflecting confidence in its GLP-1 market leadership and broader growth prospects. Further positive momentum comes from the Australian Therapeutic Goods Administration's approval of Kisunla for early Alzheimer's and a Cigna/Evernorth agreement that limits copays for Lilly’s Zepbound, enhancing its market access and reinforcing the company's commitment to innovation and expansion across multiple therapeutic areas.

Key Decisions for Investors

• Investors should assess the SiteOne Therapeutics acquisition as a strategic entry by Eli Lilly into the substantial pain management market, leveraging a validated mechanism that could offer a new growth vector and competitive positioning against peers like Vertex.
• The strong consensus among analysts, reflected in Outperform/Overweight ratings, upward earnings revisions, and price targets such as BMO's $900, Morgan Stanley's $1,133, and Bernstein's $1,100, suggests continued confidence in Eli Lilly's growth trajectory, particularly its dominance in the GLP-1 market and initiatives in obesity and Alzheimer's.
• Monitor the successful integration of SiteOne Therapeutics and the clinical advancement of STC-004, alongside the market performance of Zepbound and regulatory developments for Kisunla, as these are key potential catalysts for Eli Lilly's stock performance.